Genvec Inc (GNVC) 3.16 $GNVC
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)
GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call on March 24, 2015
PR Newswire - Tue Mar 17, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) will report financial results for the fourth quarter and year ended December 31, 2014 on Tuesday, March 24, 2015, before the U.S. financial markets open. The company's press release will be followed by a webcast conference call at 10:00 a.m. EDT to discuss GenVec's fourth quarter and 2014 financial results and 2015 business outlook.
GNVC: 3.16 (+0.07)
GenVec To Present At The 27th Annual ROTH Conference
PR Newswire - Mon Mar 02, 7:00AM CST
GenVec, Inc. (Nasdaq: GNVC) today announced that its President and CEO, Douglas J. Swirsky, will present a corporate overview at the 27th Annual ROTH Conference at 12 Noon PST/9 a.m. EST on Monday, March 9, 2015.
GNVC: 3.16 (+0.07)
Investors moving into GenVec ahead of next week's investor conference presentation
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:29AM CST
GNVC: 3.16 (+0.07)
GenVec To Present At The 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:00AM CST
GenVec, Inc. (Nasdaq: GNVC) today announced that its President and CEO, Douglas J. Swirsky, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference at 1 p.m. EST on Monday, February 9, 2015 at the Waldorf Astoria Hotel in New York City.
GNVC: 3.16 (+0.07)
GenVec, Inc. (GNVC) in Focus: Stock Jumps 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 8:18AM CST
GenVec, Inc. (GNVC) was a big mover last session, as the company saw its shares jump nearly 9% on the day.
GNVC: 3.16 (+0.07), AFFX: 12.87 (-0.07)
Can the Rally in GenVec (GNVC) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:48AM CST
Can the Rally in GenVec (GNVC) Shares Continue?
GNVC: 3.16 (+0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 11:45AM CST
EXXI: 3.83 (+0.07), EOX: 0.86 (+0.01), VTAE: 12.36 (+1.70), SN: 11.80 (+0.08), PVA: 7.64 (+0.05), ORPN: 6.30 (unch), LPI: 11.98 (+0.21), SNMX: 4.80 (-0.05), UAL: 69.45 (-0.64), RDUS: 48.61 (+0.41), GNVC: 3.16 (+0.07), GDP: 3.12 (+0.09), SFY: 2.12 (-0.07), BORN: 1.09 (-0.06), REN: 0.64 (+0.02), SCYX: 9.25 (-0.48), VGGL: 1.64 (+0.19), CMGE: 18.11 (+0.26), SLCA: 31.49 (+1.66), OAS: 13.80 (-0.16)
GenVec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:00AM CST
GNVC: 3.16 (+0.07)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 3.16 (+0.07), NVS: 101.68 (+1.81)
Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium
PR Newswire - Tue Nov 11, 6:30AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that data exploring the immune responses generated by its vaccine candidate, GV2311, were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. These data were presented by Dr. Teresa R. Johnson, Chair of the Microbiology and Immunology Department of the Edward College of Osteopathic Medicine in Virginia. GV2311 utilizes GenVec's proprietary gorilla adenovector platform. These vectors are designed to produce superior performance in gene-based vaccines, including induction of durable high-level antibody responses as well as high-level T cell responses. They have also been shown to induce increased immune responses on repeat administration.
GNVC: 3.16 (+0.07)
GenVec Achieves Milestone In Hearing And Balance Collaboration
PR Newswire - Wed Nov 05, 6:15AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved a milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine (IL) CGF166 in patients with severe hearing loss. Under the terms of the collaboration agreement this triggers a $3 million milestone payment to GenVec.
GNVC: 3.16 (+0.07), NVS: 101.68 (+1.81)
Quinterol Mallette Appointed to GenVec Board Of Directors
PR Newswire - Fri Oct 31, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
GNVC: 3.16 (+0.07)
Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 3.16 (+0.07)
GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 3.16 (+0.07)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)
GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call on March 24, 2015
PR Newswire - Tue Mar 17, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) will report financial results for the fourth quarter and year ended December 31, 2014 on Tuesday, March 24, 2015, before the U.S. financial markets open. The company's press release will be followed by a webcast conference call at 10:00 a.m. EDT to discuss GenVec's fourth quarter and 2014 financial results and 2015 business outlook.
GNVC: 3.16 (+0.07)
GenVec To Present At The 27th Annual ROTH Conference
PR Newswire - Mon Mar 02, 7:00AM CST
GenVec, Inc. (Nasdaq: GNVC) today announced that its President and CEO, Douglas J. Swirsky, will present a corporate overview at the 27th Annual ROTH Conference at 12 Noon PST/9 a.m. EST on Monday, March 9, 2015.
GNVC: 3.16 (+0.07)
Investors moving into GenVec ahead of next week's investor conference presentation
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:29AM CST
GNVC: 3.16 (+0.07)
GenVec To Present At The 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:00AM CST
GenVec, Inc. (Nasdaq: GNVC) today announced that its President and CEO, Douglas J. Swirsky, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference at 1 p.m. EST on Monday, February 9, 2015 at the Waldorf Astoria Hotel in New York City.
GNVC: 3.16 (+0.07)
GenVec, Inc. (GNVC) in Focus: Stock Jumps 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 8:18AM CST
GenVec, Inc. (GNVC) was a big mover last session, as the company saw its shares jump nearly 9% on the day.
GNVC: 3.16 (+0.07), AFFX: 12.87 (-0.07)
Can the Rally in GenVec (GNVC) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:48AM CST
Can the Rally in GenVec (GNVC) Shares Continue?
GNVC: 3.16 (+0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 11:45AM CST
EXXI: 3.83 (+0.07), EOX: 0.86 (+0.01), VTAE: 12.36 (+1.70), SN: 11.80 (+0.08), PVA: 7.64 (+0.05), ORPN: 6.30 (unch), LPI: 11.98 (+0.21), SNMX: 4.80 (-0.05), UAL: 69.45 (-0.64), RDUS: 48.61 (+0.41), GNVC: 3.16 (+0.07), GDP: 3.12 (+0.09), SFY: 2.12 (-0.07), BORN: 1.09 (-0.06), REN: 0.64 (+0.02), SCYX: 9.25 (-0.48), VGGL: 1.64 (+0.19), CMGE: 18.11 (+0.26), SLCA: 31.49 (+1.66), OAS: 13.80 (-0.16)
GenVec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:00AM CST
GNVC: 3.16 (+0.07)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 3.16 (+0.07), NVS: 101.68 (+1.81)
Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium
PR Newswire - Tue Nov 11, 6:30AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that data exploring the immune responses generated by its vaccine candidate, GV2311, were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. These data were presented by Dr. Teresa R. Johnson, Chair of the Microbiology and Immunology Department of the Edward College of Osteopathic Medicine in Virginia. GV2311 utilizes GenVec's proprietary gorilla adenovector platform. These vectors are designed to produce superior performance in gene-based vaccines, including induction of durable high-level antibody responses as well as high-level T cell responses. They have also been shown to induce increased immune responses on repeat administration.
GNVC: 3.16 (+0.07)
GenVec Achieves Milestone In Hearing And Balance Collaboration
PR Newswire - Wed Nov 05, 6:15AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved a milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine (IL) CGF166 in patients with severe hearing loss. Under the terms of the collaboration agreement this triggers a $3 million milestone payment to GenVec.
GNVC: 3.16 (+0.07), NVS: 101.68 (+1.81)
Quinterol Mallette Appointed to GenVec Board Of Directors
PR Newswire - Fri Oct 31, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
GNVC: 3.16 (+0.07)
Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 3.16 (+0.07)
GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 3.16 (+0.07)
